The Latest Breaking News from Roche

Roche, a biopharmaceutical company and ZS a global management consulting and technology firm, on Friday announced the inauguration of a Business Operations Center for Advanced Analytics and Business Insights in Chennai.

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Bayer stock surged to an eight-month high Wednesday after the company named former Roche exec Bill Anderson as its new chief executive.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Merck is navigating a looming patent expiration for its blockbuster Keytruda. Now, Merck stock is trading at its highest point in decades.

While a recession in 2023 looks inevitable amid lingering macro headwinds, experts believe it to be mild. Moreover, amid high hopes for a Santa Claus rally, quality stocks Stellantis (STLA), Albertsons Companies (ACI), Poseida Therapeutics (PSTX), and Civeo (CVEO) could be ideal buys under $30 now. Keep reading….

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out